I.C. Olsen

Latest

• Assessments of the unmet need in the management of patients with rheumatoid arthritis: Analyses from the NOR-DMARD registry
• Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases
• Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
• The frequency of intrapartum caesarean section use with the WHO partograph versus Zhang's guideline in the Labour Progression Study (LaPS): a multicentre, cluster-randomised controlled trial
• Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes
• Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
• Discrepancies in risk age and relative risk estimations of cardiovascular disease in patients with inflammatory joint diseases
• Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: Experiences from the nationwide NOCAR project
• Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women—A double-blind, randomized non-inferiority trial
• Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: Data from real-life follow-up in the NOR-DMARD study
• Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol
• The Impact of Ultrasound on the Use and Efficacy of Intraarticular Glucocorticoid Injections in Early Rheumatoid Arthritis: Secondary Analyses From a Randomized Trial Examining the Benefit of Ultrasound in a Clinical Tight Control Regimen
• 4$β$-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State
• Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register
• Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis
• Cardiovascular disease risk profiles in inflammatory joint disease entities
• Efficacy of infliximab biosimilars in patients with Crohn's disease – Authors' reply
• Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-näive patients classified according to the 2010 ACR/EULAR criteria
• Sleep disturbance in patients with rheumatoid arthritis is related to fatigue, disease activity, and other patient-reported outcomes
• Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
• Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: Results from the Swedish biologics register
• Achievement of remission and low disease activity definitions in patients with rheumatoid arthritis in clinical practice: Results from the Nor-Dmard study
• Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach
• Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases
• First step in the development of an ultrasound joint inflammation score for rheumatoid arthritis using a data-driven approach
• Involvement of the multidisciplinary team and outcomes in inpatient rehabilitation among patients with inflammatory rheumatic disease
• Involvement of the multidisciplinary team and outcomes in inpatient rehabilitation among patients with inflammatory rheumatic disease Rehabilitation, physical therapy and occupational health
• Predictive value of arterial stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with rheumatoid arthritis
• Sustained improvement of arterial stiffness and blood pressure after long-term rosuvastatin treatment in patients with inflammatory joint diseases: Results from the rora-as study
• The association of hypertension with asymptomatic cardiovascular organ damage in rheumatoid arthritis
• Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial
• Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: A cross-sectional comparative study
• CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: Results after 5-year follow-up
• Disease activity and left ventricular structure in patients with rheumatoid arthritis
• Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: A cross-sectional study
• EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: An audit of the success of implementation in a rheumatology outpatient clinic
• Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis
• Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: Results from the Oslo rheumatoid arthritis register
• Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: Results from the RORA-AS statin intervention study
• Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: The rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study
• Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: Results from the NOR-DMARD study 2000-2010
• A large conditioned pain modulation response is not related to a large blood pressure response: A study in healthy men
• Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: Results from a followup MRI Study of 254 patients in clinical remission or low disease activity
• Efficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: A randomized controlled pilot study
• NOR-DMARD data management: Implementation of data capture from electronic health records
• Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: A cross-sectional study
• Associations between APOE Genotypes and Disease Susceptibility, Joint Damage and Lipid Levels in Patients with Rheumatoid Arthritis
• Carotid plaque characteristics and disease activity in rheumatoid arthritis
• $ømega$-3 fatty acid treatment in multiple sclerosis (OFAMS study): A randomized, double-blind, placebo-controlled trial
• A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation
• An approach to combining parallel and cross-over trials with and without run-in periods using individual patient data
• Consequences of handling missing data for treatment response in osteoarthritis: A simulation study
• Bioavailability of EPA and DHA delivered by gelled emulsions and soft gel capsules
• NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial